← Leaderboards
Matthew B Renfrow
University Of Alabama At Birmingham
$7,936,462
Attributed
$11,161,370
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.4M · FY2008–25$2.5M$1.9M$1.3M$625K$0
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$11,161,370 · 7
By mechanism
R01$6,326,449 · 2
R44$1,930,902 · 1
S10$1,687,401 · 1
P01$617,411 · 1
R21$387,500 · 1
R43$211,707 · 1
Top collaborators
- Jan Novak5 shared
- William J. Placzek3 shared
- Tomasz Szul2 shared
- Janusz Tucholski1 shared
Most similar at University Of Alabama At Birmingham
Same institution · by research overlap
- Henna Budhwani$2,967,729
- Comfort Chu Enah$559,226
- Alan Thevenet N. Tita$31,628,801
- William J. Placzek$3,567,295
- Janusz Tucholski$617,411
Others in their field
Top investigators on “Series”
- Lawrence Corey · Fred Hutchinson Cancer Center$445,660,381
- Kiran Datta · Leidos Biomedical Research, Inc.$292,634,066
- David R. Weir · University Of Michigan At Ann Arbor$276,156,779
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$231,733,045
- Dennis R. Burton · Scripps Research Institute$199,946,411
- Joel A Lipkin · Four Points Technology, Llc$183,862,844
Research focus
SeriesPolysaccharidesSiteExhibitsPublishingMolecularSamplingGlycosylationGlycoproteinsIga1AffectSerumAntigen-Antibody ComplexLaboratoriesAreaLectinComplexProteinsAntibodiesInsightFutureBaseChronicHeterogeneity
Grant awards (24)
GalNAc-specific measurement of Galactose-deficient IgA1 as a Biomarker for IgA nephropathy$953,146
R44 · FY2025 · DK
Defining the impact of glycan-microdomains of the HIV-1 Env glycan shield$718,601
R01 · FY2025 · AI · contact PI
GalNAc-specific measurement of Galactose-deficient IgA1 as a Biomarker for IgA nephropathy$977,756
R44 · FY2024 · DK
Defining the impact of glycan-microdomains of the HIV-1 Env glycan shield$718,601
R01 · FY2024 · AI · contact PI
Orbitrap Eclipse Tribrid Mass Spectrometer for Biomedical High end USERS$1,687,401
S10 · FY2023 · OD · contact PI
Defining the impact of glycan-microdomains of the HIV-1 Env glycan shield$718,601
R01 · FY2023 · AI · contact PI
Defining the impact of glycan-microdomains of the HIV-1 Env glycan shield$718,601
R01 · FY2022 · AI · contact PI
Defining the impact of glycan-microdomains of the HIV-1 Env glycan shield$718,601
R01 · FY2021 · AI · contact PI
Project 2: Design and Development of Third Generation RXR Rexinoids as Potential Chemoprevention Agents$131,141
P01 · FY2021 · CA · contact PI
Project 2: Design and Development of Third Generation RXR Rexinoids as Potential Chemoprevention Agents$271,589
P01 · FY2020 · CA · contact PI
Utilizing IgG Autoantibodies as Biomarkers in IgA Nephropathy$211,707
R43 · FY2020 · DK
Analytical tools for the analysis of clustered O-glycans in clinical samples$352,112
R01 · FY2019 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$368,870
R01 · FY2018 · GM · contact PI
Project 2: Design and Development of Third Generation RXR Rexinoids as Potential Chemoprevention Agents$214,681
P01 · FY2018 · CA · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$90,988
R01 · FY2018 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$368,870
R01 · FY2017 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$368,870
R01 · FY2016 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$35,000
R01 · FY2016 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$282,932
R01 · FY2014 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$278,255
R01 · FY2013 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$287,167
R01 · FY2012 · GM · contact PI
Analytical tools for the analysis of clustered O-glycans in clinical samples$300,380
R01 · FY2011 · GM · contact PI
Accurate profiles of IgA1 O-glycan heterogeneity in IgA nephropathy$181,250
R21 · FY2009 · DK · contact PI
Accurate profiles of IgA1 O-glycan heterogeneity in IgA nephropathy$206,250
R21 · FY2008 · DK · contact PI